« Return to News | CROs/Service Providers

Averion Plans to Go Private

Tuesday, September 8, 2009 04:37 PM

Averion, a contract research organization (CRO) specializing in oncology, cardiovascular diseases and medical devices, has filed a statement with the Securities and Exchange Commission (SEC) as it plans to go from a publicly traded company to one that is private.

The move will reduce the costs and administrative burdens of running a public company, Averion said, as well as allow shareholders with small holdings in the company to immediately realize the value of their investment.

Averion shareholders have approved a reverse stock split, which would give shareholders with less than 20,500 shares of common stock a cash payment of $0.01 per share. Following the transaction, the total number of shareholders will be less than 300, enabling the company to cease registration of its common stock under SEC rules.

“Averion is a successful provider of clinical research services in a very competitive business environment. The increasing cost and time associated with public company regulatory compliance required a significant amount of expense and management resources with no tangible benefit to our shareholders,” said board chairman James McGuire in a statement.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.